- Study builds on clinical benefit reported in heavily pretreated
platinum resistant ovarian cancer patients treated with dual and
triple combination of COM701 + nivolumab ± BMS-986207
- Initial findings expected by the end of 2023
HOLON, ISRAEL, June 22,
2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that the first patient has been dosed in
the triple immunotherapy combination proof-of-concept study
evaluating COM701, Compugen's potential first-in-class anti-PVRIG
antibody, with COM902, Compugen's potential best-in-class
anti-TIGIT antibody and pembrolizumab in patients with platinum
resistant ovarian cancer.
"We are very excited that the first patient with platinum
resistant ovarian cancer has been dosed with the triple
immunotherapy combination of COM701, COM902 and pembrolizumab in
our proof-of-concept study. This milestone keeps us on track to
report initial findings by the end of this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of
Compugen. "The goal of the study is to build on the encouraging
data previously reported by us at the ESMO Immuno-Oncology Congress
2022, with the dual and triple blockade of PVRIG and PD-1 with or
without TIGIT. We expect that this study will help us to better
understand the contribution of the components and contribute to our
ongoing biomarker work to try and identify the patients most likely
to respond, with the purpose of building a path to
registration."
"Despite recent advances in the treatment of patients with
platinum resistant ovarian cancer, there remains a significant
unmet need for new treatment options for these patients," said Dr.
Manish Sharma, Associate Director of
Clinical Research at START Midwest in Grand Rapids, Michigan. "I am very excited to
participate in this proof-of-concept study with the novel triple
immunotherapy combination of COM701, COM902 and pembrolizumab. Our
initial observation is that this combination is well tolerated by
patients as observed in our microsatellite stable colorectal cancer
proof-of-concept study initiated recently. I hope this
differentiated approach of blocking three pathways in the DNAM-1
axis, PVRIG, TIGIT and PD-1 will result in additional treatment
options for patients with platinum resistant ovarian cancer."
Details on the study:
This proof-of-concept study (NCT04354246) is an open label study
evaluating the combination of COM701 with COM902 and pembrolizumab
in up to 40 patients with high grade platinum resistant epithelial
ovarian cancer including patients with fallopian tube cancer and
primary peritoneal cancer who have received up to 3 lines of prior
therapy for platinum resistant ovarian cancer. The study includes
patients with all histologies. The initiation of the study is based
on Phase 1 cohort expansion data reported at ESMO-IO 2022, showing
a favorable safety and tolerability profile and durable anti-tumor
activity with the combination of COM701 and nivolumab ± BMS-986207
in platinum resistant ovarian cancer patients.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is
a potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares
are listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, our expectation to
report initial findings by the end of 2023; our expectation that
this study will help us to better understand the contribution of
the components and contribute to our ongoing biomarker work to try
and identify the patients most likely to respond, with the purpose
of building a path to registration; and statement related to the
hope this differentiated approach of blocking three pathways in the
DNAM-1 axis, PVRIG, TIGIT and PD-1 will result in additional
treatment options for patients with platinum resistant ovarian
cancer.These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance, or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks: In
the near term, Compugen is highly dependent on the success of
COM701 and of COM902; Compugen may not be able to advance its
internal clinical stage programs through clinical development or
manufacturing or successfully partner or commercialize them, or
obtain marketing approval, either alone or with a collaborator, or
may experience significant delays in doing so; Clinical development
involves a lengthy and expensive process, with an uncertain outcome
and Compugen may encounter substantial delays or even an inability
to begin clinical trials for any specific product or may not be
able to conduct or complete its trials on the timelines it expects;
Compugen has limited experience in the development of therapeutic
product candidates, and it may be unable to implement its business
strategy. These risks and other risks are more fully discussed in
the "Risk Factors" section of Compugen's most recent Annual Report
on Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-doses-first-patient-in-triple-immunotherapy-combination-com701-com902-and-pembrolizumab--platinum-resistant-ovarian-cancer-proof-of-concept-study-301857724.html
SOURCE Compugen Ltd.
